title: Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
authors: S
authors: S
authors: Crippa
authors: S
authors: S
authors: Partelli
authors: L
authors: L
authors: Boninsegna
authors: M
authors: M
authors: Falconi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000145:classification* / Q000188:drug therapy / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000145:classification* / Q000188:drug therapy / Q000473:pathology; D011758:Pyrroles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077210:Sunitinib; D014944:World Health Organization
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus